查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1797939

全球生育治療服務市場：2032 年預測 - 按治療類型、不孕症原因、最終用戶和地區進行分析

Fertility Services Market Forecasts to 2032 - Global Analysis By Treatment Type (Assisted Reproductive Technology and Artificial Insemination ), Infertility Cause, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球生育服務市場預計在 2025 年達到 494 億美元，到 2032 年將達到 858 億美元，預測期內的複合年成長率為 8.2%。

生育服務涵蓋一系列旨在幫助個人或夫婦受孕的治療、診斷程序和支持性解決方案。這些服務包括輔助生殖技術 (ART)，例如體外受精 (IVF)、子宮內人工授精 (IUI)、生育力保存、荷爾蒙療法和診斷檢測。市場成長的驅動力包括：不孕症上升、生育延遲以及生殖保健意識的增強，而技術進步和專業生育診所及照護網路的普及也推動了這個市場的成長。

不孕不育率上升

根據世界衛生組織 (WHO) 2023 年的報告，全球約六分之一的成年人面臨不孕症的困擾，約佔成年人口的 17.5%。肥胖、慢性壓力和過量飲酒等不良生活習慣，以及卵巢症候群 (PCOS) 等常見疾病，是導致不孕率下降的重要原因。此外，都市區推遲受孕的趨勢日益明顯，老年女性卵子品質下降，也推動了對先進不孕症治療的需求，為全球服務供應商創造了巨大的市場機會。

不孕不育治療費用高昂

不孕症治療，尤其是體外受精（IVF）和先進的輔助生殖技術，需要大量的資金投入，通常超過一個治療週期。許多患者需要多次嘗試才能成功受孕，這進一步增加了整體費用負擔。此外，由於各地區不孕症治療的保險保障範圍有限，夫妻不得不自掏腰包。這些經濟限制尤其影響中等收入者，他們的收入通常過高，不符合援助計畫的資格，但仍缺乏經濟能力來輕鬆負擔全面的不孕症治療。

在新興市場擴張

生育診所和專科治療中心在亞太地區、拉丁美洲和新興國家正在迅速擴張。政府推出的生殖保健舉措，加上人們對生育治療方案日益成長的認知，正在創造有利的市場條件。此外，新興市場的醫療旅遊業蓬勃發展，為國際患者提供了經濟實惠的生育治療方案，使這些地區成為全球生育中心。

文化和宗教的反對

傳統觀念對不孕症治療（尤其是涉及捐贈配子和代孕的治療）在某些群體中引發了抵制。反對人工生殖介入的宗教教義限制了某些群體對不孕症的市場接受度和利用率。此外，圍繞不孕症問題的社會污名化阻礙了許多夫婦尋求必要的治療，從而降低了整體市場需求。此外，各國法律體制和倫理考量的差異可能會使服務提供者的業務複雜化，並限制其擴大策略。

COVID-19的影響：

新冠疫情最初擾亂了全球的生育服務，許多診所在封鎖期間暫停了非必要的治療。然而，隨著各國政府加強通訊協定，幫助生育中心重新開放，市場展現驚人的韌性。許多夫婦利用這段時間規劃治療，導致服務恢復後需求增加。此外，疫情帶來的壓力以及封鎖期間受孕延遲導致生育服務的使用率上升，促進了市場在疫情後的復甦和加速成長。

預計女性不孕症領域將成為預測期內最大的領域

由於各種生理和生活方式因素影響女性生殖功能，預計女性不孕症領域將在預測期內佔據最大的市場佔有率。卵巢症候群 (PCOS)、子宮內膜結核和卵巢早衰等疾病的盛行率不斷上升，顯著增加了女性不孕症。此外，都市區職業婦女生育年齡延遲的趨勢日益明顯，導致生育能力老齡化下降，對專科治療的需求也日益增加。先進的女性不孕症評估診斷技術，加上卵子冷凍和荷爾蒙療法等創新治療方案，進一步鞏固了該領域的主導地位。

預計在預測期內，不孕症治療診所部門的複合年成長率最高。

生育診所細分市場預計將在預測期內實現最高成長率，這得益於其專業化和全面的治療服務。這些專門的機構提供最先進的設備、專業知識以及專為生殖保健設計的個人化治療通訊協定。該行業受益於全球獨立生育中心的日益增多，尤其是在採用人工智慧輔助胚胎選擇和延時成像等先進技術的已開發地區。此外，生育診所能夠在同一地點提供標準和複雜的治療，加上高成功率以及與精子銀行和卵子庫的合作，預計將推動其持續成長。

比最大的地區

預計北美將在預測期內佔據最大的市場佔有率。該地區的主導地位歸功於其先進的醫療基礎設施、對不孕症治療的高度認知以及覆蓋多個地區的全面保險覆蓋。尤其是美國，憑藉其領先的不孕症診所、技術創新以及輔助生殖技術的廣泛接受，正在推動該地區的成長。此外，北美夫婦推遲生育的趨勢日益明顯、不孕症盛行率的上升以及支持性的法律規範，都是鞏固該地區市場領導地位的因素。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這得益於快速的經濟發展和醫療基礎設施的改善。包括中國、印度和東南亞在內的許多國家，生育診所的開設數量和治療可近性正在顯著增加。可支配收入的增加、人們對生育治療方案的認知度不斷提高以及對現代生殖技術的日益接受，都促成了這一顯著的成長軌跡。此外，政府對生殖保健的支持舉措，加上該地區龐大的人口和不斷演變的社會對生育治療的態度，使亞太地區成為最具活力和持續成長潛力的市場之一。

不孕不育的原因

  • 男性不孕
  • 女性不孕症
  • 不明原因的不孕症

免費客製化服務

此報告的訂閱者可以從以下免費自訂選項中選擇一項：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 簡介

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 主要研究資料
    • 二手研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 市場機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 企業之間的競爭

5. 全球生育治療服務市場（依治療類型）

  • 輔助生殖技術（ART）
    • 體外受精（IVF）
      • 新鮮非供體
      • 冷凍非捐贈者
      • 新捐款者
      • 凍結捐贈者
    • 卵細胞質內單一精蟲顯微注射術（ICSI）
    • 配子輸卵管植入（GIFT）
    • 受精卵輸卵管內移植（ZIFT）
    • 其他輔助生殖技術
  • 人工授精（AI）
    • 子宮內授精（IUI）
    • 子宮頸內授精（ICI）
    • 其他人工授精

6. 全球生育治療服務市場（依不孕症原因分類）

  • 男性不孕
  • 女性不孕症
  • 不明原因的不孕症

7. 全球生育治療服務市場（依最終用戶）

  • 不孕不育診所
  • 醫院
  • 手術中心
  • 精子庫
  • 臨床研究所

8. 全球生育治療服務市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第9章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併與收購（M&A）
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章：企業概況

  • CooperSurgical, Inc.
  • Merck KGaA
  • Vitrolife
  • Ferring Pharmaceuticals
  • IVI RMA Global
  • Kindbody
  • Inception Fertility
  • Progyny, Inc.
  • Monash IVF Group
  • Virtus Health
  • Boston IVF
  • Shady Grove Fertility
  • Carrot Fertility
  • Thermo Fisher Scientific Inc.
  • Cook Medical
  • FUJIFILM Irvine Scientific
  • Hamilton Thorne Ltd.
  • Nova IVF Fertility
  • Genea Biomedx
Product Code: SMRC30309

According to Stratistics MRC, the Global Fertility Services Market is accounted for $49.4 billion in 2025 and is expected to reach $85.8 billion by 2032 growing at a CAGR of 8.2% during the forecast period. Fertility services encompass a range of medical treatments, diagnostic procedures, and support solutions designed to assist individuals or couples in achieving pregnancy. These include assisted reproductive technologies (ART) such as in vitro fertilization (IVF), intrauterine insemination (IUI), fertility preservation, hormonal therapies, and diagnostic testing. Market growth is driven by rising infertility rates, delayed childbearing, and increasing awareness of reproductive health, supported by technological advancements and expanding access to specialized fertility clinics and care networks.

Market Dynamics:

Driver:

Rising Infertility Rates

According to the World Health Organization's 2023 report, approximately one in six adults worldwide face infertility challenges, affecting about 17.5% of the adult population. Lifestyle modifications, including obesity, chronic stress, and excessive alcohol consumption, and prevalent medical conditions such as polycystic ovary syndrome (PCOS) significantly contribute to declining fertility rates. Furthermore, the growing trend of delayed parenthood in urban populations has resulted in decreased egg quality among older women, intensifying the demand for advanced fertility interventions and creating substantial market opportunities for service providers globally.

Restraint:

High cost of fertility treatments

Fertility procedures, particularly in vitro fertilization (IVF) and advanced assisted reproductive technologies require considerable financial investment that often extends beyond single treatment cycles. Many patients require multiple attempts to achieve successful pregnancy outcomes, compounding the overall cost burden. Additionally, limited insurance coverage for fertility treatments in various regions forces couples to bear out-of-pocket expenses. This economic constraint particularly affects middle-income families who earn too much to qualify for assistance programs yet not enough to afford comprehensive fertility treatments comfortably.

Opportunity:

Expansion in emerging markets

Countries across Asia-Pacific, Latin America, and developing regions are witnessing rapid expansion of fertility clinics and specialized treatment centers. Government initiatives supporting reproductive healthcare access, coupled with growing awareness about fertility preservation options, create favorable market conditions. Moreover, the rise of medical tourism in emerging markets offers cost-effective fertility solutions to international patients, establishing these regions as global fertility hubs.

Threat:

Cultural and religious opposition

Traditional beliefs regarding fertility treatments, particularly those involving donor gametes or surrogacy arrangements, create resistance among certain populations. Religious doctrines opposing artificial reproductive interventions limit market acceptance and utilization rates in specific communities. Additionally, societal stigma surrounding infertility issues prevents many couples from seeking necessary treatments, reducing overall market demand. Furthermore, varying legal frameworks and ethical considerations across different countries create operational complexities for service providers, potentially limiting expansion strategies.

Covid-19 Impact:

The COVID-19 pandemic initially disrupted fertility services globally, with many clinics temporarily suspending non-essential procedures during lockdowns. However, the market demonstrated remarkable resilience as governments supported the reopening of infertility centers with enhanced safety protocols. Many couples utilized this period for treatment planning, leading to increased demand following service resumption. Additionally, pandemic-induced stress and delayed pregnancies during lockdowns subsequently drove higher fertility service utilization rates, contributing to market recovery and growth acceleration in the post-pandemic period.

The female infertility segment is expected to be the largest during the forecast period

The female infertility segment is expected to account for the largest market share during the forecast period due to various physiological and lifestyle factors affecting women's reproductive health. Rising prevalence of conditions such as polycystic ovary syndrome (PCOS), endometrial tuberculosis, and premature ovarian failure significantly contribute to female infertility rates. Moreover, the increasing trend of delayed childbearing among career-focused women in urban areas results in age-related fertility decline, driving demand for specialized treatments. Advanced diagnostic techniques for female fertility assessment, coupled with innovative treatment options including egg freezing and hormonal therapies, further solidify this segment's leadership position.

The fertility clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the fertility clinics segment is predicted to witness the highest growth rate, driven by their specialized focus and comprehensive treatment offerings. These dedicated facilities provide state-of-the-art equipment, specialized expertise, and personalized care protocols specifically designed for reproductive treatments. The segment benefits from the increasing establishment of standalone fertility centers worldwide, particularly in developed regions where advanced technologies such as AI-driven embryo selection and time-lapse imaging are being implemented. Additionally, fertility clinics' ability to offer both standard and complex treatments under one roof, combined with their higher success rates and partnerships with sperm and egg banks, positions them for sustained growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. The region's dominance stems from advanced healthcare infrastructure, high awareness levels about fertility treatments, and comprehensive insurance coverage in many areas. The United States particularly drives regional growth with its presence of leading fertility clinics, technological innovations, and widespread acceptance of assisted reproductive technologies. Additionally, the growing trend of delayed parenthood among North American couples, combined with increasing prevalence of infertility and supportive regulatory frameworks, reinforces the region's market leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by rapid economic development and improving healthcare infrastructure. Countries including China, India, and Southeast Asian nations are witnessing substantial increases in fertility clinic establishments and treatment accessibility. Rising disposable incomes, growing awareness about fertility preservation options, and increasing acceptance of modern reproductive technologies contribute to this remarkable growth trajectory. Furthermore, government initiatives supporting reproductive healthcare, coupled with the region's large population base and evolving social attitudes toward fertility treatments, position Asia Pacific as the most dynamic and promising market for sustained expansion.

Key players in the market

Some of the key players in Fertility Services Market include CooperSurgical, Inc., Merck KGaA, Vitrolife, Ferring Pharmaceuticals, IVI RMA Global, Kindbody, Inception Fertility, Progyny, Inc., Monash IVF Group, Virtus Health, Boston IVF, Shady Grove Fertility, Carrot Fertility, Thermo Fisher Scientific Inc., Cook Medical, FUJIFILM Irvine Scientific, Hamilton Thorne Ltd., Nova IVF Fertility, and Genea Biomedx.

Key Developments:

In February 2024, CooperSurgical has acquired the fertility business from the LifeGlobal(R) Group, a pioneer and global leader within IVF. With this acquisition, we are taking yet another step towards providing our customers with the strongest possible solutions that consist of high-quality products and services, to help specialists improve patient outcomes and increase chances of a healthy pregnancy.

In September 2023, Merck, a leading science and technology company, is launching a comprehensive Fertility Benefit program in October 2023 that will offer employees financial support for fertility treatments. The program will be launched in eight markets: Germany, the United Kingdom, Switzerland, China, India, Taiwan, Brazil, and Mexico. To date, Merck offers similar benefits to employees in the United States, Canada, and Japan. An expansion of the offering to Merck employees in further countries is planned to start next year.

In July 2023, To extend the benefits of genomic testing research for reproductive health labs, Thermo Fisher Scientific launched two new next-generation sequencing-based options to support preimplantation genetic testing-aneuploidy (PGT-A) used commonly to inform in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research. The Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit mark the first research use reproductive health assays available on the Ion Torrent Genexus Integrated Sequencer, delivering complete workflows from sample to result for aneuploidy analysis.

Treatment Types Covered:

  • Assisted Reproductive Technology (ART)
  • Artificial Insemination (AI)

Infertility Causes:

  • Male Infertility
  • Female Infertility
  • Unexplained Infertility

End Users Covered:

  • Fertility Clinics
  • Hospitals
  • Surgical Centers
  • Cryobanks
  • Clinical Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Fertility Services Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Assisted Reproductive Technology (ART)
    • 5.2.1 In-Vitro Fertilization (IVF)
      • 5.2.1.1 Fresh Non-Donor
      • 5.2.1.2 Frozen Non-Donor
      • 5.2.1.3 Fresh Donor
      • 5.2.1.4 Frozen Donor
    • 5.2.2 Intracytoplasmic Sperm Injection (ICSI)
    • 5.2.3 Gamete Intrafallopian Transfer (GIFT)
    • 5.2.4 Zygote Intrafallopian Transfer (ZIFT)
    • 5.2.5 Other Assisted Reproductive Technologies
  • 5.3 Artificial Insemination (AI)
    • 5.3.1 Intrauterine Insemination (IUI)
    • 5.3.2 Intracervical Insemination (ICI)
    • 5.3.3 Other Artificial Inseminations

6 Global Fertility Services Market, By Infertility Cause

  • 6.1 Introduction
  • 6.2 Male Infertility
  • 6.3 Female Infertility
  • 6.4 Unexplained Infertility

7 Global Fertility Services Market, By End User

  • 7.1 Introduction
  • 7.2 Fertility Clinics
  • 7.3 Hospitals
  • 7.4 Surgical Centers
  • 7.5 Cryobanks
  • 7.6 Clinical Research Institutes

8 Global Fertility Services Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 CooperSurgical, Inc.
  • 10.2 Merck KGaA
  • 10.3 Vitrolife
  • 10.4 Ferring Pharmaceuticals
  • 10.5 IVI RMA Global
  • 10.6 Kindbody
  • 10.7 Inception Fertility
  • 10.8 Progyny, Inc.
  • 10.9 Monash IVF Group
  • 10.10 Virtus Health
  • 10.11 Boston IVF
  • 10.12 Shady Grove Fertility
  • 10.13 Carrot Fertility
  • 10.14 Thermo Fisher Scientific Inc.
  • 10.15 Cook Medical
  • 10.16 FUJIFILM Irvine Scientific
  • 10.17 Hamilton Thorne Ltd.
  • 10.18 Nova IVF Fertility
  • 10.19 Genea Biomedx

List of Tables

  • Table 1 Global Fertility Services Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Fertility Services Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 3 Global Fertility Services Market Outlook, By Assisted Reproductive Technology (ART) (2024-2032) ($MN)
  • Table 4 Global Fertility Services Market Outlook, By In-Vitro Fertilization (IVF) (2024-2032) ($MN)
  • Table 5 Global Fertility Services Market Outlook, By Fresh Non-Donor (2024-2032) ($MN)
  • Table 6 Global Fertility Services Market Outlook, By Frozen Non-Donor (2024-2032) ($MN)
  • Table 7 Global Fertility Services Market Outlook, By Fresh Donor (2024-2032) ($MN)
  • Table 8 Global Fertility Services Market Outlook, By Frozen Donor (2024-2032) ($MN)
  • Table 9 Global Fertility Services Market Outlook, By Intracytoplasmic Sperm Injection (ICSI) (2024-2032) ($MN)
  • Table 10 Global Fertility Services Market Outlook, By Gamete Intrafallopian Transfer (GIFT) (2024-2032) ($MN)
  • Table 11 Global Fertility Services Market Outlook, By Zygote Intrafallopian Transfer (ZIFT) (2024-2032) ($MN)
  • Table 12 Global Fertility Services Market Outlook, By Other Assisted Reproductive Technologies (2024-2032) ($MN)
  • Table 13 Global Fertility Services Market Outlook, By Artificial Insemination (AI) (2024-2032) ($MN)
  • Table 14 Global Fertility Services Market Outlook, By Intrauterine Insemination (IUI) (2024-2032) ($MN)
  • Table 15 Global Fertility Services Market Outlook, By Intracervical Insemination (ICI) (2024-2032) ($MN)
  • Table 16 Global Fertility Services Market Outlook, By Other Artificial Inseminations (2024-2032) ($MN)
  • Table 17 Global Fertility Services Market Outlook, By Infertility Cause (2024-2032) ($MN)
  • Table 18 Global Fertility Services Market Outlook, By Male Infertility (2024-2032) ($MN)
  • Table 19 Global Fertility Services Market Outlook, By Female Infertility (2024-2032) ($MN)
  • Table 20 Global Fertility Services Market Outlook, By Unexplained Infertility (2024-2032) ($MN)
  • Table 21 Global Fertility Services Market Outlook, By End User (2024-2032) ($MN)
  • Table 22 Global Fertility Services Market Outlook, By Fertility Clinics (2024-2032) ($MN)
  • Table 23 Global Fertility Services Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 24 Global Fertility Services Market Outlook, By Surgical Centers (2024-2032) ($MN)
  • Table 25 Global Fertility Services Market Outlook, By Cryobanks (2024-2032) ($MN)
  • Table 26 Global Fertility Services Market Outlook, By Clinical Research Institutes (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.